FASS.se FÖR ALLMÄNHETEN

• LÄKEMEDELSFAKTA
• LÄKARBOK
• PATIENTFORUM
• LÄKEMEDELSUNIVERSITETET
• LÄNKAR
• INFO & HJÄLP

Data om kliniska prövningar kommer från IFPMA Clinical Trials Portal.

Kliniska prövningar

Kartan visar var de kliniska prövningarna i resultatet är lokaliserade

• 1 :
  Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate
  
  
  The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.
  
  
• 2 :
  Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
  
  
  The purpose of this clinical research study is to understand the safety and efficacy of BMS-354825 in patients with chronic, accelerated, or blast phase chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia (ALL) who are resistant to or intolerant of imatinib mesylate (Gleevec).
  
  
• 3 :
  Campath, Chronic Lymphocytic Leukemia (CLL), safety confirmatory study
  
  
  The purpose of this study is to confirm the safety profile of alemtuzumab 30 mg (the US/EU approved dose) in Japanese patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL).
  Trial Locations: unknown Japan unknown
  
  
• 4 :
  An Open-label, Randomized Study of Dasatinib vs. High-dose (800 mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib
  
  
  The purpose of this study is to compare the efficacy of dasatinib to high-dose imatinib (800 mg) in patients with chronic phase chronic myeloid leukemia (CML) who achieved a suboptimal response after at least 3 months of imatinib (400 mg) monotherapy. The safety of these treatments will also be studied.
  Trial Locations: Charleroi Belgium Province du Hainaut, unknown France unknown, unknown France unknown, unknown Portugal Lisboa, unknown Russia unknown, Valencia Spain Valencian Community, unknown Spain Murcia, unknown United Kingdom Greater London
  
  
• 5 :
  Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia
  
  
  The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML
  Trial Locations: Houston United States Texas
  
  
• 6 :
  A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
  
  
  The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.
  Trial Locations: Edmonton Canada Alberta, Hamilton Canada Ontario, Montréal Canada Quebec, Toronto Canada Ontario, Vancouver Canada British Columbia, Ann Arbor United States Michigan, Atlanta United States Georgia, Aurora United States Colorado, Boston United States Massachusetts, Charleston United States South Carolina, Chattanooga United States Tennessee, Cincinnati United States Ohio, Cleveland United States Ohio, Colorado Springs United States Colorado, Corona United States California, Daytona Beach United States Florida, Detroit United States Michigan, Indianapolis United States Indiana, Iowa City United States Iowa, Jupiter United States Florida, Kansas City United States Kansas, Lawrenceville United States Georgia, Lawton United States Oklahoma, Lexington United States Kentucky, Louisville United States Kentucky, New York City United States New York, Portland United States Oregon, Portland United States Oregon, Providence United States Rhode Island, Salina United States Kansas, Santa Fe United States New Mexico, Sheboygan United States Wisconsin, Spokane United States Washington, Tulsa United States Oklahoma, unknown United States Connecticut, unknown United States Indiana
  
  
• 7 :
  Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
  
  
  The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.
  Trial Locations: Boston United States Massachusetts, Boston United States Massachusetts, Boston United States Massachusetts, Buffalo United States New York, Gainesville United States Florida, Houston United States Texas, Houston United States Texas, La Jolla United States California, Portland United States Oregon, Seattle United States Washington
  
  
• 8 :
  Phase II study of KW-0761 in subjects with CCR4-positive adult T-cell leukemia-lymphoma
  
  
  To evaluate the efficacy, safety and pharmacokinetic profiles of KW-0761, the anti-CC chemokine receptor 4 (CCR4) antibody, when administered weekly for 8 weeks as an intravenous infusion at a dose of 1.0 mg/kg in relapsed subjects with CCR4-positive adult T-cell leukemia-lymphoma.
  
  
• 9 :
  Osteoporosis in Children With ALL
  
  
  Hypothesis: Pediatric patients with acute lymphoblastic leukemia, treated with chronic glucocorticoids as a part of the leukemia treatment protocol, will have an increased incidence and severity of osteoporosis.
  Trial Locations: Kansas City United States Missouri
  
  
• 10 :
  Clofarabine in Adult Patients With Advanced Solid Tumors
  
  
  Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This research study of clofarabine will be used for advanced cancer in persons in which drugs are no longer effective or no reliable effective treatment is available. The purpose of this study is to find the answers to the following research questions: 1. What is the largest dose of clofarabine that can be safely administered as an IV infusion (over at least 2 hours) once a week for 3 weeks (days 1, 8 and 15) followed by 1 week of rest and repeated every 28 days? 2. What are the side effects of clofarabine when given on this schedule? 3. How much clofarabine is in the blood at specific times after administration and how does the body get rid of the drug? Once the MTD/RP2D is established, patients will be enrolled at the MTD/RP2D regardless of the PK data with cardiac assessments done every other cycle. 4. Will clofarabine help treat a specific cancer?
  Trial Locations: Dallas United States Texas, Tyler United States Texas
  
  

UPP